Skip to the beginning of the images gallery

Accounting at Biovail - Revised

Mary Gillett ; Mary-Jane Mastrandrea ; Jessica Frisch

Reference: IVEY-9B09B004-E
Year: 2003
Number of pages: 19
Geographic Setting: Canada
Publication Date: Jan 7, 2009
Fecha de edición: Jun 4, 2009
Source: Ivey Business School (Canada)
Type of Document: Case
Industry Setting: Manufacturing;

Grouped product items
Format	Language	Reference	Use	Qty	Price	Preview
pdf	English	IVEY-9B09B004-E			As low as €8.20	Preview

You already have a subscription

To order please contact the person in charge of academic purchases in your university.

You'll be able to order once your profile has been validated.

Description

Biovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers the implications of this report for the company and for the audit committee.

Keywords

Corporate governance Financial Reports/Disclosure